



Claims

1. A bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



5 wherein

A represents



wherein

Q_1 and Q_4 independently represent direct bond or methylene;

10 Q_2 represents CHR^2 , or CO,

Q_3 represents CHR^3 , or CO,

wherein

15 R^2 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

R^3 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

with the proviso that

20 Q_1 and Q_4 can not be direct bond at the same time;

R^2 and R^3 can not be hydrogen at the same time;

when Q_1 represents direct bond,

R^3 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_5 represents CH or CR^5 ,

wherein

R^5 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy,

5 or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

Q_6 represents CH or CR^6 ,

wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy,

10 or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

with the proviso that Q_5 and Q_6 can not be CH at the same time;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

15 -X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond; and

-Y- represents CH_2 , O or NH; and

20 R^1 represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6} alkyl)amino, N,N-

di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆alkoxycarbonyl, sulfon-
amide, C₁₋₆ alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl, C₁₋₆ alkyl-
carbamoyl, C₃₋₈cycloalkyl, heterocycle,

5 C₁₋₆ alkyl [wherein said alkyl is optionally substituted by cyano, nitro,
hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-,
or tri-halogen],

C₁₋₆ alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or
tri- halogen],

10 C₁₋₆ alkylthio [wherein said alkylthio is optionally substituted by mono-,
di-, or tri- halogen],


phenyl, benzyl and phenoxy ,

15 [wherein said phenyl, phenyl moiety of said benzyl or phenyl
moiety of said phenoxy are optionally substituted by
halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino,
N,N-di(C₁₋₆ alkyl)amino, N-(C₃₋₈cycloalkyl)amino, C₁₋₆
alkoxycarbonyl, C₁₋₆alkoxycarbonyl or C₁₋₆ alkyl].

2. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or
stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

20 A represents



Q₁ and Q₄ represent methylene;

Q₂ represents CHR² or CO,

wherein

R^2 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Q_3 represents CHR^3 or CO ,

5 wherein

R^3 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Q_5 represents CH ;

Q_6 represents CR^6 ,

10 wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

15 $-X-$ represents a bond, $-O-$ or $-N(R^4)-$,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, $-X-$ represents a bond;

$-Y-$ represents CH_2 , O or NH ; and

20 R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

25 said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, $N-(C_{1-6}alkyl)amino$, $N,N-di(C_{1-6}alkyl)amino$, $N-(C_{3-8} cycloalkyl)amino$, $C_{1-6}alkoxycarbonyl$,

sulfonamide, C₁₋₆ alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl, C₁₋₆ alkyl-carbamoyl, C₃₋₈cycloalkyl, heterocycle,

C₁₋₆ alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy-carbonyl or mono-, di-, or tri-halogen],

C₁₋₆ alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri-halogen],

C₁₋₆ alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri-halogen],


phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkoxy-carbonyl or C₁₋₆ alkyl].

3. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₁ represents methylene;

Q₄ represents direct bond;

Q₂ represents CHR² or CO,

wherein

R² represents hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

Q_3 represents CHR^3 ,

wherein

R^3 represents hydrogen;

m represents an integer from 0 to 3;

5 p represents an integer 0 or 1;

$-X-$ represents a bond, $-O-$ or $-N(R^4)-$,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, $-X-$ represents a bond;

10 $-Y-$ represents CH_2 , O or NH ; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

15 said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, $N-(C_{1-6}alkyl)amino$, $N,N-di(C_{1-6}alkyl)amino$, $N-(C_{3-8} cycloalkyl)amino$, $C_{1-6}alkoxycarbonyl$, sulfonamide, $C_{1-6} alkanoyl$, $N-(C_{1-6}alkanoyl)amino$, carbamoyl, $C_{1-6} alkylcarbamoyl$, $C_{3-8}cycloalkyl$, heterocycle,

20 $C_{1-6} alkyl$ [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, $C_{1-6} alkoxycarbonyl$ or mono-, di-, or tri-halogen],

$C_{1-6} alkoxy$ [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

25 $C_{1-6} alkylthio$ [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,


[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl].

5

4. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



10

Q₁ and Q₄ represents methylene;

Q₂ represents CHR²,

wherein

R² represents hydrogen;

15

Q₃ represents CHR³,

wherein

R³ represents hydrogen, hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

20

-X- represents a bond, -O- or -N(R⁴)-,

wherein R⁴ is hydrogen or C₁₋₆ alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH₂, O or NH; and

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆alkoxycarbonyl, sulfonamide, C₁₋₆ alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₃₋₈cycloalkyl, heterocycle,

C₁₋₆ alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen],

C₁₋₆ alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C₁₋₆ alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],


phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl].

5. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q_1 and Q_4 represent methylene;

Q_2 represents CHR^2 ,

wherein

5 R^2 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_3 represents CHR^3 ,

wherein

R^3 represents hydrogen;

m represents an integer from 1 to 3;

10 p represents 0 or 1;

$-X-$ represents a bond, $-O-$ or $-N(R^4)-$,

wherein

R^4 is hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, $-X-$ represents a bond;

15 $-Y-$ represents CH_2 , O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

20 said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, $N-(C_{1-6}alkyl)amino$, $N,N-di(C_{1-6}alkyl)amino$, $N-(C_{3-8} cycloalkyl)amino$, $C_{1-6}alkoxycarbonyl$, sulfonamide, $C_{1-6} alkanoyl$, $N-(C_{1-6}alkanoyl)amino$, carbamoyl, $C_{1-6} alkylcarbamoyl$, $C_{3-8}cycloalkyl$, heterocycle,

C₁₋₆ alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy-carbonyl or mono-, di-, or tri-halogen],

5

C₁₋₆ alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C₁₋₆ alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,

10


[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈cycloalkyl)amino, C₁₋₆alkoxy-carbonyl, C₁₋₆ alkoxy-carbonyl or C₁₋₆ alkyl].

15

6. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₅ represents CH;

20

Q₆ represent CR⁶,

wherein

R⁶ represents hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkanoyloxy, or C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

m represents an integer from 0 to 3;

25

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R⁴)-,

wherein

R⁴ represents hydrogen or C₁₋₆ alkyl,

with the proviso that when m is 0, -X- represents a bond;

5 -Y- represents NH, O or CH₂; and

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,


wherein

said phenyl, naphthyl, pyridyl, or pyrimidyl are optionally substituted by one or two of substituents selected from the group consisting of halogen, nitro, C₁₋₆alkyl, trifluoroC₁₋₆alkyl, C₁₋₆alkoxy, trifluoroC₁₋₆alkoxy and C₁₋₆alkanoylamino.

7. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₁ and Q₄ represents methylene;

Q₂ represents CHR²,

wherein

R² represents hydrogen;

20 Q₃ represents CHR³,

wherein

R³ represents hydrogen, hydroxy, C₁₋₆alkoxy or C₁₋₆alkanoyloxy;

Q_5 represents CH;

Q_6 represents CR^6 ,

wherein

R^6 represents hydroxy;

5 m represents an integer 2;

p represents an integer 0;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 is hydrogen or C_{1-6} alkyl,

10 with the proviso that when m is 0, -X- represents a bond;

-Y- represents NH or O; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

15 said phenyl, naphthyl, pyridyl, or pyrimidyl are optionally substituted by one or two of substituents selected from the group consisting of chloro, bromo, fluoro, nitro, methyl, methoxy, trifluoromethyl, trifluoroethyl, trifluoromethoxy, trifluoroethoxy, acetamido and propionylamino;

8. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said bicyclic amide,
20 carbamate or urea derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-[4-(trifluoromethyl)benzyl]urea;

4-(trifluoromethyl)benzyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-3-[4-(trifluoromethyl)phenyl]propan-
amide;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-(2-{{[4-(trifluoromethyl)phenyl]-amino}ethyl}urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-(2-[4-(trifluoromethyl)phenoxy]-ethyl}urea;

5 2-{{[4-(trifluoromethyl)phenyl]amino}ethyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;

2-[4-(trifluoromethyl)phenoxy]ethyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;and

10 N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

N-(2-{{[4-chloro-3-(trifluoromethyl)phenyl]amino}ethyl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

N-{2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl}-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

15 N-(2-{{[4-chloro-3-(trifluoromethyl)phenyl]amino}ethyl)-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea; and

N-{2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl}-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea

9. A medicament comprising the bicyclic amide, carbamate or urea derivative of the formula
20 (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
10. The medicament as claimed in claim 9, further comprising one or more pharmaceutically acceptable excipients.
11. The medicament as claimed in claim 9, wherein said bicyclic amide, carbamate or urea
25 derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
12. The medicament as claimed in claim 9 for the treatment and/or prevention of an urological disorder or disease.

13. The medicament as claimed in claim 12, wherein said urological disorder or disease is urge urinary incontinence or overactive bladder.
14. The medicament as claimed in claim 9 for the treatment and/or prevention of pain.
- 5 15. The medicament as claimed in claim 14, wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.
16. The medicament as claimed in claim 9 for the treatment and/or prevention of a disorder or disease related to pain.
17. The medicament as claimed in claim 16, wherein said disorder or disease related to pain is neuralgia, neuropathies, algnesia, nerve injury, ischaemia, neurodegeneration, or stroke.
- 10 18. The medicament as claimed in claim 9 for the treatment and/or prevention of an inflammatory disorder or disease.
19. The medicament as claimed in claim 18, wherein said inflammatory disorder or disease is asthma or COPD.
- 15 20. Use of compounds according to claim 1 for manufacturing a medicament for the treatment and/or prevention of an urological disorder or disease.
21. Use of compounds according to claim 1 for manufacturing a medicament for the treatment and/or prevention of pain.
22. Use of compounds according to claim 1 for manufacturing a medicament for the treatment and/or prevention of an inflammatory disorder or disease.
- 20 23. Process for controlling an urological disorder or disease in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.
24. Process for controlling pain in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.
- 25 25. Process for controlling an inflammatory disorder or disease in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.